Development of medications for alcohol use disorders: recent advances and ongoing challenges.
about
Topiramate in the treatment of substance-related disorders: a critical review of the literatureA double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patientsA double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patientsChallenges and opportunities for medications development in alcoholism: an international perspective on collaborations between academia and industry.Addressing tobacco use disorder in smokers in early remission from alcohol dependence: the case for integrating smoking cessation services in substance use disorder treatment programsA literature review of cost-benefit analyses for the treatment of alcohol dependence.Alcohol and opioid dependence medications: prescription trends, overall and by physician specialtyMedications development to treat alcohol dependence: a vision for the next decade.Effects of adrenal sensitivity, stress- and cue-induced craving, and anxiety on subsequent alcohol relapse and treatment outcomesExpanding the role of health services research as a tool to reduce the public health burden of alcohol use disorders.Alcohol dependence, withdrawal, and relapse.Ginseng Extract G115 Attenuates Ethanol-Induced Depression in Mice by Increasing Brain BDNF Levels.Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance.Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.Letter to Editor in Response to Johnson's Commentary (2017) on the Witkiewitz and Colleagues (2017) Article.
P2860
Q24633145-9E3DA783-2457-4C86-B2DB-5703F36E7FC4Q30417813-C0E561F0-519E-410F-A003-162D8BCF7BBFQ30422068-A171F4FC-B535-4FD2-A82F-5AB0B44ED50FQ30438009-06B25167-F7CA-456D-843C-D893670F3C59Q30477221-7C60803C-152A-478C-BC1D-86DEDEB6682EQ35195707-3108E3A7-272E-423D-9AE4-3A66CFA68458Q35195803-68C9B802-3E08-4849-862E-91469DB9DE91Q36357552-9E6B20C6-30F4-432D-9544-3021AD1F12BFQ36891423-CD25B7E4-A832-4064-A4CF-E6BAA38EF819Q37328160-8628D6B1-B51C-4B12-A0B2-BEE7AEC43327Q37386560-6759FE38-6B3F-446A-A576-66E02E8D0DA8Q42368213-DC42C6D3-D7DF-44CF-AB52-FA58CF61DA6FQ42380034-DAD33A55-FE10-4586-B79D-988757CA9C83Q46941434-8B903AAA-B311-4DB1-9683-A0D1DD18C515Q47732515-9DEAE1F5-E39D-4FAD-8BC9-EE17C550DCFB
P2860
Development of medications for alcohol use disorders: recent advances and ongoing challenges.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Development of medications for ...... vances and ongoing challenges.
@ast
Development of medications for ...... vances and ongoing challenges.
@en
type
label
Development of medications for ...... vances and ongoing challenges.
@ast
Development of medications for ...... vances and ongoing challenges.
@en
prefLabel
Development of medications for ...... vances and ongoing challenges.
@ast
Development of medications for ...... vances and ongoing challenges.
@en
P2093
P2860
P1476
Development of medications for ...... vances and ongoing challenges.
@en
P2093
Joanne Fertig
Margaret Mattson
Raye Z Litten
P2860
P304
P356
10.1517/14728214.10.2.323
P407
P577
2005-05-01T00:00:00Z